Búsqueda Imágenes Maps Play YouTube Noticias Gmail Drive Más »
Iniciar sesión
Usuarios de lectores de pantalla: deben hacer clic en este enlace para utilizar el modo de accesibilidad. Este modo tiene las mismas funciones esenciales pero funciona mejor con el lector.


  1. Búsqueda avanzada de patentes
Número de publicaciónUS20050196342 A1
Tipo de publicaciónSolicitud
Número de solicitudUS 11/055,544
Fecha de publicación8 Sep 2005
Fecha de presentación10 Feb 2005
Fecha de prioridad9 Ene 1992
También publicado comoCA2127705A1, CA2127705C, DE69328354D1, DE69328354T2, EP0620744A1, EP0620744B1, EP0972527A2, EP0972527A3, US5558856, US5827502, US20030059373, US20050031543, WO1993013808A2, WO1993013808A3
Número de publicación055544, 11055544, US 2005/0196342 A1, US 2005/196342 A1, US 20050196342 A1, US 20050196342A1, US 2005196342 A1, US 2005196342A1, US-A1-20050196342, US-A1-2005196342, US2005/0196342A1, US2005/196342A1, US20050196342 A1, US20050196342A1, US2005196342 A1, US2005196342A1
InventoresJo Klaveness, Pal Rongved, Lars Stubberud
Cesionario originalJo Klaveness, Pal Rongved, Lars Stubberud
Exportar citaBiBTeX, EndNote, RefMan
Enlaces externos: USPTO, Cesión de USPTO, Espacenet
Contrast agents
US 20050196342 A1
Contrast agents comprising microbubble-generating carbohydrate microparticles having a surfactant admixed within the microparticulate structure, with the proviso that the surfactant is not a C10-20 fatty acid, are disclosed. Processes for preparing contrast agents also are disclosed.
Previous page
Next page
1-13. (canceled)
14. The method of generating an enhanced echocardiographic image of a human or non-human body comprising: administering into the pulmonary system of said body an echocardiographic contrast enhancing amount of a contrast agent comprising gasmicrobubble-generating aggregates of microparticles; applying to a part of said body ultrasound at a frequency of 0.1 to 15 MHZ; and generating said image; said microparticles comprising a water soluble matrix material and a surfactant, the microbubbles generated by said aggregates comprising SF6 or a fluorinated low molecular weight hydrocarbon, said aggregates being 20-125 Φm in size and said microparticles having an average size of 0.1 to 50 Φm.
15. The method as claimed in claim 14 in which the surfactant is selected from the group consisting of straight chain aliphatic carboxylic acids and salts, sorbitan esters and mono- and di-glycerides thereof; aralkanoic acids and the salts thereof; steroid acids; sterols; straight chain aliphatic alcohols; phospholipids; alkali metal alkyl sulphates and sulphonated esters; polyoxyethylene-polyoxypropylene copolymers; polyoxyethylated sorbitan esters; and mixtures of any of the foregoing.
16. The method as claimed in claim 14 in which the surfactant comprises a lipophilically modified carbohydrate.
17. The method as claimed in claim 14 in which the surfactant is present in an amount of 0.1-2.0% w/w relative to the water soluble matrix.
18. The method as claimed in claim 14 for which the microbubbles generated by said aggregates contain air in admixture with said SF6 or fluorinated hydrocarbon.
19. The method as claimed in claim 14 for which the microbubbles generated by said aggregates comprise carbon tetrafluoride.
20. The method as claimed in claim 14 in which the water soluble matrix is a carbohydrate.
21. The method as claimed in claim 20 in which the carbohydrate is a polysaccharide.
22. The method as claimed in claim 20 in which the carbohydrate is a sugar alcohol.
23. The method as claimed in claim 14 which is non-contrast giving before use, but which becomes effective on administration.
24. The method as claimed in claim 15 which is non-contrast giving before use, but which becomes effective on administration.
25. The method as claimed in claim 16 which is non-contrast giving before use, but which becomes effective on administration.
26. The method as claimed in claim 17 which is non-contrast giving before use, but which becomes effective on administration.
27. The method as claimed in claim 18 which is non-contrast giving before use, but which becomes effective on administration.
28. The method as claimed in claim 19 which is non-contrast giving before use, but which becomes effective on administration.
  • [0001]
    This invention relates to novel contrast agents, more particularly to new microparticulate contrast agents of use in diagnostic imaging.
  • [0002]
    It is well known that ultrasonic imaging comprises a potentially valuable diagnostic tool, for example in studies of the vascular system, particularly in cardiography, and of tissue microvasculature. A variety of contrast agents has been proposed to enhance the acoustic images so obtained, including suspensions of solid particles, emulsified liquid droplets, gas microbubbles and encapsulated gases or liquids. It is generally accepted that low density contrast agents which are easily compressible are particularly efficient in terms of the acoustic backscatter they generate, and considerable interest has therefore been shown in the preparation of gas-containing and gas-generating systems.
  • [0003]
    Initial studies involving free gas microbubbles generated in vivo by intracardiac injection of physiologically acceptable substances have demonstrated the potential efficiency of such bubbles as contrast agents in echocardiography; such techniques are severely limited in practice, however, by the short lifetime of the free bubbles. Interest has accordingly been shown in methods of generating and/or stabilising gas microbubbles for echocardiography and other ultrasonic studies, for example using emulsifiers, oils, thickeners or sugars.
  • [0004]
    Techniques involving the use of sugars in ultrasound contrast agents are described in, for example, U.S. Pat. No. 4,681,119, U.S. Pat. No. 4,442,843 and U.S. Pat. No. 4,657,756, which disclose the use of particulate solids having a plurality of gas-filled voids and preferably also a plurality of nuclei for microbubble formation. EP-A-0123235 and EP-A-0122624 suggest ultrasound contrast agents consisting of surfactant-coated or surfactant-containing gas-containing microparticles which may include a variety of sugars. Where surfactant-containing microparticles are described, these are prepared simply by commingling the surfactant with the microparticulate materials, e.g. by trituration.
  • [0005]
    DE-A-3834705 proposes the use of suspensions containing microparticles of mixtures of at least one C10-20, tatty acid with at least one non-surface active substance, including sugars such as cyclodextrins, monosaccharides, disaccharides or trisaccharides, as well as other polyols and inorganic and organic salts; in practice only the use of galactose as the non-surface active material and only the use of saturated fatty acids are exemplified. The microparticulate materials are typically prepared by coprecipitating the fatty acid and non-surface active substance and comminuting the resulting product, e.g. using an air-jet mill.
  • [0006]
    One material of, the type described in DE-A-3834705, SHU 508 (Levovist®), is described in the following publications:
    • Schlief, R. et al., Circulation Supplement III (1990) 82, p. 28; Schartl, M. et al., Circulation Supplement III (1990) 82, p. 261; Fritzsch, T. et al., Invest. Radiol. (1990) 25 (Suppl), pp. 160-161; Schlief, R. et al., Echocardiography (1990) 7, pp. 61-64; Loughery, E. J. et al., Echocardiography (1990) 7, pp. 279-292; and Smith, M. D. et al., JACC (1989) 13, pp. 1622-1628.
  • [0008]
    Gas-containing contrast media are also known to be effective in magnetic resonance, (MR) imaging, e.g. as susceptibility contrast, agents which will act to reduce, MR signal intensity. Oxygen-containing contrast media also represent potentially useful paramagnetic MR contrast agents.
  • [0009]
    Furthermore, in the field of X-ray imaging it has been observed that gases such as carbon dioxide may be used as negative oral contrast agents.
  • [0010]
    A general disadvantage of most of the existing gas-containing/gas-generating particulate contrast agents such as the sugar-based agents discussed above is their relative lack of stability in vivo. This is a particular problem in applications such as echocardiography, where there is a need for improved contrast agents combining sufficient stability and small microbubble size (typically less than about 10 μm, preferably less than about 7 μm) to permit passage through the pulmonary capillary bed and so allow enhanced visualisation of the left side of the heart, it preferably for more than one passage of circulation. There is accordingly a need for contrast agents which generate microbubble systems exhibiting good stability while still providing an effective level of contrast efficiency.
  • [0011]
    The present invention is based on our finding that contrast agents comprising microparticles of a carbohydrate having a surfactant admixed therewith (but excluding the previously disclosed mixtures of galactose and saturated C10-20 fatty acids) may be used to generate microbubble systems exhibiting enhanced contrast effect and/or stability relative to previously proposed carbohydrate-based contrast agents. In the ultrasound field this may be demonstrated by, for example, in vitro measurements of initial attenuation levels and the half lives of the attenuative effect; a useful indication of the combined effect of these properties is the integral obtained by determining the area under the curve of a plot of attenuation against time.
  • [0012]
    The term “surfactant” as used herein means any compound having amphiphilic properties capable of modifying surface tension.
  • [0013]
    Thus, according to one aspect of the present invention, there are provided contrast agents comprising microbubble-generating carbohydrate microparticles having a surfactant admixed within the microparticulate structure, with the proviso that the surfactant is not a saturated C10-20 fatty acid when the microparticulate carbohydrate is galactose.
  • [0014]
    The microparticulate carbohydrate is preferably water soluble, and subject to the foregoing proviso may for example be selected from hexoses such as glucose, fructose or galactose; disaccharides such as sucrose, lactose or maltose; pentoses such as arabinose, xylose or ribose; and polysaccharides such as α-, β- and γ-cyclodextrins, maltodextrin and glycogen; the term “carbohydrate” as used herein is also intended to embrace sugar alcohols, e.g. alditols such as mannitol or sorbitol. Microparticles of the above carbohydrates will normally have gas present as an inclusion in the voids of their crystal structure and/or adhered to their surface, which gas may generate microbubbles when, for example, the microparticles are suspended or dissolved in an injectable carrier liquid, for example water for injection, an aqueous solution of one or more inorganic salts (e.g. physiological saline or a physiological buffer solution), an aqueous solution of a monosaccharide (e.g. glucose or galactose) or disaccharide (e.g. lactose), or an aqueous solution of a physiologically tolerable monohydric or polyhydric alcohol (e.g. ethanol, propanol, isopropanol, ethylene glycol, propylene glycol, glycerine or polyethylene glycol).
  • [0015]
    In addition to or alternatively to air, any biocompatible gas may be employed in the contrast agents of the invention, for example nitrogen, oxygen, hydrogen, nitrous oxide, carbon dioxide, helium, argon, sulphur hexafluoride and low molecular weight optionally fluorinated hydrocarbons such as methane, acetylene or carbon tetrafluoride. The term “gas” as used herein includes any substance in the gaseous form at 37° C. The gas may be contained in the contrast agent in such a way that before use the product is non-contrast giving but becomes effective on administration, e.g. as a result of the gas forming microbubbles as a soluble carbohydrate matrix dissolves.
  • [0016]
    Additionally or alternatively the carbohydrate may incorporate one or more gas precursors, including carbonates and bicarbonates (e.g. sodium or ammonium bicarbonate) and aminomalonate esters.
  • [0017]
    Subject to the foregoing proviso a wide variety of surfactants may be used in the ultrasound contrast agents of the invention; it will of course be appreciated that the surfactant is required to be biocompatible, i.e. that it should be physiologically tolerable in the quantities in which it is to be administered. The surfactant is advantageously biodegradable in vivo or otherwise readily eliminable from the system.
  • [0018]
    The surfactant may, for example, be an amphiphilic lipid, e.g. selected from fatty acids and salts (e.g. alkali metal salts) thereof, steroid acids, sterols, phospholipids and glycolipids. Such lipids-include high molecular weight (e.g. C10-50) straight chain saturated and unsaturated aliphatic acids, such as capric, palmitic, hexadecanedioic, stearic, linolenic, behenic, docosanedioic and melissic acids; aralkanoic acids, e.g. phenyl lower alkanoic acids such as 2-phenylbutyric acid; salts of any of the foregoing acids; mono- and di-glycerides, for example glyceryl esters of high molecular weight (e.g. C10-50) aliphatic acids, such as glyceryl monolaurate; cholanic acids such as 5β-cholanic acid; cholesterol; sorbitan esters of fatty acids such as Span-type materials; high molecular weight (e.g. c10-50) straight chain aliphatic alcohols such as stearyl alcohol and cetyl alcohol; phospholipids such as phosphatidyl choline (lecithin) and dioleoylphosphatidyl ethanolamine (DOPE); and mixtures thereof.
  • [0019]
    Other surfactants which may be employed include anionic surfactants, for example alkali metal alkyl sulphates such as sodium lauryl sulphate and sulphonated esters such as sodium dioctyl sulphosuccinate (docusate); and non-ionic surfactants, for example polyoxyethylene-polyoxyproplyene copolymers (e.g. poloxamers such as Pluronic F68) and polyoxyethylated sorbitan esters (e.g. polysorbates such as Tween-type materials).
  • [0020]
    The surfactant moiety may if desired be covalently linked to a substrate such as a carbohydrate prior to its admixture with the principal microparticulate carbohydrate. Thus, for example, a fatty acid such as palmitic acid (preferably in the form of a reactive derivative such as a corresponding acyl halide) may be used to esterify a (preferably appropriately O-protected) sugar such as galactose and the resulting lipophilically modified carbohydrate used as the surfactant in accordance with the invention.
  • [0021]
    The surfactant may, for example, be present in an amount of 0.01-5.0 wt. %, preferably 0.1-2.0 wt. %, relative to the microparticulate carbohydrate.
  • [0022]
    The contrast agents of the invention may be used in a variety of diagnostic imaging techniques, including ultrasound, MR and X-ray imaging. Their uses in diagnostic ultrasonic imaging and MR imaging, e.g. as susceptibility contrast agents, constitute preferred features of the invention.
  • [0023]
    The contrast agents of the invention may be prepared by any convenient method which leads to physical admixture of the surfactant within the microparticulate structure of the carbohydrate and to production of microparticles of the desired size.
  • [0024]
    In one preferred method according to the invention the carbohydrate and the surfactant are each dissolved in appropriate mutually miscible solvents (e.g. water in the case or the carbohydrate and a lower alkanol such as ethanol in the case of lipid surfactants such as fatty acids), the resulting solutions are mixed, the solvents are removed (e.g. by evaporation under reduced pressure), and the resulting solid mixture is micronised to yield the desired microparticles. It will be appreciated that all such operations should be effected under sterile conditions.
  • [0025]
    In an alternative method according to the invention a (preferably aqueous) solution of the carbohydrate is mixed with a liposome-forming material (e.g. a thin film of a lipid such as lecithin formed on the inner surface of the mixing vessel by evaporating the solvent from a solution of the lipid in an appropriate organic solvent, for example a chlorinated hydrocarbon such as chloroform) so as to form a liposome-containing carbohydrate solution from which the solvent may be removed (e.g. by freeze-drying) to yield a product comprising carbohydrate-containing liposomes; this product may be micronised to given microparticles of the desired size.
  • [0026]
    In, general conventional micronisation techniques such as grinding or milling may be employed in processes according to the invention. Ball-milling of the solid mixture has been found to be particularly advantageous, permitting the preparation of microparticles in the form of aggregates, (for example having an aggregate size of 20-125 micrometers, such as 30-50 micrometers) of particles having a particle size of, for example, 1-50 micrometers, such as 1-10 micrometers. Such aggregates will tend to contain a substantial volume of air adsorbed on their surfaces and entrained in voids such as interparticle cavities or at grain boundaries between the crystallites. The particle size may, for example, be selected to be substantially commensurate with the desired microbubble size. In ultrasonic applications such as echocardiography, in order to permit free passage through the pulmonary system and to achieve resonance with the preferred imaging frequencies of about 0.1-15 MHz, it may be convenient to employ microbubbles and microparticles having an average size of 0.1-10 μm, e.g. 1-7 μm; the use of microparticles of average size 1-4 μm to generate microbubbles with an average size of 4-7 μm is generally advantageous. Substantially larger bubbles and particles, e.g. with average sizes up to 500 μm, may however be useful in other applications, for example gastrointestinal imaging.
  • [0027]
    Ultrasound contrast agents in the form of microparticles comprising a microbubble-generating carbohydrate in admixture with an amphiphilic organic acid containing in excess of 20 carbon atoms are the subject matter of our international patent application cofiled herewith and claiming priority from British patent application No. 9200387.0.
  • [0028]
    The following non-limitative Examples serve to illustrate the invention:—
  • EXAMPLES 1-18
  • [0000]
    General Procedure
  • [0029]
    D-(+)-galactose (10.0 g) was dissolved in distilled water (14.2 g) at 50° C., sterile filtered and cooled on ice to a temperature of 4˜8° C. The stated amounts of the surfactants (in % w/w relative to the galactose) listed in Table I were each dissolved in the amount of 96% ethanol (or water in Examples 5 and 6) shown in the Table, at 50˜78° C., and the resulting solution was sterile filtered and then aseptically added to the cold aqueous galactose solution under stirring. The resulting mixture was evaporated to dryness under reduced pressure (10 torr, 40° C.), and the resulting solid product was dried in a desiccator overnight and then ground for 10 minutes under aseptic conditions in a stainless steel ball mill having a 50 ml grinding cup and 3×20 mm bails (Retsch centrifugal ball mill, Sl). The ground product was dried in a desiccator for 24 hours.
    Amount of
    Amount of ethanol
    Example Surfactant (or water)
    No. Surfactant (% w/w) (g)
    1 Lecithin 1.0 1.2
    2 0.2 1.2
    3 Sodium Lauryl Sulphate 1.0 1.0 (water)
    4 0.1 1.0 (water)
    5 Span 80 1.0 1.2
    6 0.1 1.2
    7 Span 85 1.0 1.2
    8 0.1 1.2
    9 Pluronic F68 1.0 1.2
    10 0.1 1.2
    11 Sodium Docusate 1.0 1.2
    12 0.1 1.2
    13 DOPE 1.0 1.2
    14 0.1 1.2
    15 α-Glyceryl Monolaurate 0.2 3.2
    Glyceryl Tripalmitate 0.2
    Cholesterol 0.2
    Cholesterol Acetate 0.2
    Cholesterol Benzoate 0.2
    16 α-Glyceryl Monolaurate 0.02 1.2
    Glyceryl Tripalmitate 0.02
    Cholesterol 0.02
    Cholesterol Acetate 0.02
    Cholesterol Benzoate 0.02
    17 Hexadecanedioic Acid 0.2 1.2
    18 Linolenic Acid 1.0 1.2
  • EXAMPLES 19-22
  • [0030]
    The general procedure for Examples 1-18 was repeated except that the D-(+)-galactose was replaced by the carbohydrates listed in Table II, in the amounts and using the quantities of water shown, and that the surfactant used was palmitic acid (0.2% w/w relative to the carbohydrate) dissolved in 96% ethanol (1.2 g).
    Amount of Amount of
    Example Microbubble-generating Carbohydrate water
    No. Carbohydrate (g) (g)
    19 Xylose (BDH) 10.0 14.2
    20 Maltodextrin 10.0 14.2
    21 Glycogen (Merck) 5.0 17.2
    22 α-Cyclodextrin (Sigma) 5.0 12.2
  • EXAMPLE 23 6-O-Palmitoyl-D-galactopyranose/galactose mixtures (A) 6-O-Palmitoyl-1,2,3,4-diisopropylidene-D-galactopyranose
  • [0031]
    1,2,3,4-Diisopropylidene-D-galactopyranose (Sigma, 13.4 g, 51.3 mmol) and triethylamine (7.15 ml, 51.3 mmol) were dissolved in methylene chloride (150 ml) and cooled to 0° C. Palmitoyl chloride (Aldrich, 14.1 g, 51.3 mmol) dissolved in methylene chloride (100 ml) was added dropwise with stirring over 1 h. The cooling bath was removed and the reaction mixture was stirred overnight. Precipitated triethylamine hydrochloride was removed by filtration, the filtrate was transferred to a separating funnel and extracted with water (3×50 ml), dried over MgSO4 and the solvent was removed in vacuo. The residue was a light brownish oil which solidified to waxy crystals. Crude yield: 23 g. The crude product was used without further purification. A small aliquot was recrystallized for characterisation FT-IR:CO-1734 cm−1.
  • [0032]
    13C-NMR: CO-ester 179. Mp. 124-127° C.
  • (B) 6-O-Palmitoyl-D-galactopyranose
  • [0033]
    6-O-Palmitoyl-1,2,3,4-diisopropylidene-D-galactopyranose (6 g) was dissolved in acetic acid (25 ml) and heated to 100° C. under nitrogen for 6 h. During subsequent cooling to room temperature, the product precipitated from the solvent, and was left at room temperature overnight. The crystals were collected by filtration and dried under vacuum. Yield:3.3 g. The product was characterized by FT-IR:CO-1734 cm−1; OH-3464 cm−1.
  • (C) 6-O-Palmitoyl-D-galactopyranose/galactose mixtures
  • [0034]
    (i) D-(+)-galactose (2 g) was dissolved in purified water (2.879) and sterile filtered. 6-O-Palmitoyl-D-galactopyranose (0.25 g) prepared as described in (B) above was dissolved in ethanol (3 g) and sterile filtered. The solution of the palmitoyl-galactopyranose was added to the galactose solution under stirring and the whole mixture was taken to dryness under vacuum (10 torr, 50° C.). The product was dried in a desiccator overnight.
  • [0035]
    (ii) The procedure of (i) was repeated using 6-O-palmitoyl-D-galactopyranose (0.50 g) dissolved in ethanol (6 g).
  • EXAMPLE 24
  • [0000]
    Freeze-dried liposomes containing D-(+)-galactose particles
  • [0036]
    1 ml 100 mg/ml phosphatidylcholine was dissolved in 10 ml chloroform. The mixture was poured into a round bottom flask, and the organic phase was evaporated at 40° C. in such a way that a thin film of the 35′ phosphatidylcholine was, formed on the inner surface of the flask. 10 ml of a sterile, pyrogen free 40% aqueous D-(+)-galactose solution was then added at 40° C. and the flask was kept rotating for 1 hour. The aqueous solution containing liposomes and dissolved galactose was then freeze-dried for 24 hours, and the resulting product consisting of freeze-dried galactose and freeze dried galactose-filled liposomes was then ground in a ball-mill to yield a product with a particle size distribution of 1-20 μm.
  • EXAMPLE 25
  • [0000]
    Echogenicity In Vitro
  • [0037]
    10 ml of propylene glycol mixed with 90 ml of 5% dextrose in water was used as a carrier liquid for determining the echogenicity of products according to the Examples. 1.0 g of each product to be tested was dispersed in 3.0 ml of the carrier liquid and shaken for seconds. The resulting mixture was added to 52 ml of 5% human serum albumin infusion solution in the measurement cell and the acoustic effects of the products were investigated by measuring the acoustic transmission through the samples using a 5 MHz broadband transducer in a pulse-reflection technique. The temperature in the measurement cell was stabilised to 37° C. and circulation of the liquid was maintained by means of stirring at a constant rate. Ultrasound transmission through the samples was measured as a function of time over a duration of 390 seconds. Results were normalized to measurements on a reference consisting of, 55 ml of 59 human serum albumin infusion solution.
  • [0038]
    Results for representative exemplified products and comparative results for unmodified milled D-(+)-galactose are shown in the accompanying drawing as FIG. 1. It will be apparent that these products exhibit a strong effect on ultrasonic attenuation in vitro, an effect which persisted for several minutes.
Citas de patentes
Patente citada Fecha de presentación Fecha de publicación Solicitante Título
US3557294 *12 Oct 196719 Ene 1971Allied ChemFluorinated ethers as inhalation convulsants
US3650831 *10 Mar 196921 Mar 1972Armour Dial IncMethod of cleaning surfaces
US3663687 *26 Jun 196816 May 1972Minnesota Mining & MfgBiodegradable parenteral microspherules
US3720761 *14 Oct 196813 Mar 1973Hunter WInjectable radio-pharmaceutical scanning agent and preparation
US3832457 *17 Jun 197027 Ago 1974Rikagaku KenkyushoFerrite contrast media with metallic oxides
US3900420 *14 Sep 197219 Ago 1975Felix SebbaMicrogas emulsions and method of forming same
US3932805 *9 Ago 197313 Ene 1976Kichizo NiwaMethod of obtaining internal information of a measuring target from the out-side by the application of a nuclear magnetic resonance phenomenon
US3968203 *26 Ago 19696 Jul 1976Jerome G. SpitzerAerosol astringent composition
US4027007 *13 Mar 197331 May 1977Colgate-Palmolive CompanyAntiperspirants formulated with borax
US4101435 *14 Jun 197618 Jul 1978Meito Sangyo Kabushiki KaishaMagnetic iron oxide-dextran complex and process for its production
US4107288 *9 Sep 197515 Ago 1978Pharmaceutical Society Of VictoriaInjectable compositions, nanoparticles useful therein, and process of manufacturing same
US4244179 *9 Nov 197813 Ene 1981Kainov Gennady PAnnular combustion chamber for gas turbine engines
US4247406 *23 Abr 197927 Ene 1981Widder Kenneth JIntravascularly-administrable, magnetically-localizable biodegradable carrier
US4265251 *28 Jun 19795 May 1981Rasor Associates, Inc.Method of determining pressure within liquid containing vessel
US4276885 *4 May 19797 Jul 1981Rasor Associates, IncUltrasonic image enhancement
US4316391 *13 Nov 197923 Feb 1982Ultra Med, Inc.Flow rate measurement
US4329332 *16 Jul 197911 May 1982Patrick CouvreurBiodegradable submicroscopic particles containing a biologically active substance and compositions containing them
US4331654 *13 Jun 198025 May 1982Eli Lilly And CompanyMagnetically-localizable, biodegradable lipid microspheres
US4335094 *1 Jun 197815 Jun 1982Mosbach Klaus HMagnetic polymer particles
US4371516 *17 Jul 19811 Feb 1983John Wyeth & Brother LimitedArticles for carrying chemicals
US4427649 *31 Dic 198124 Ene 1984Imperial Chemical Industries LimitedPharmaceutical compositions
US4442843 *17 Nov 198117 Abr 1984Schering, AgMicrobubble precursors and methods for their production and use
US4452773 *5 Abr 19825 Jun 1984Canadian Patents And Development LimitedMagnetic iron-dextran microspheres
US4466442 *13 Oct 198221 Ago 1984Schering AktiengesellschaftCarrier liquid solutions for the production of gas microbubbles, preparation thereof, and use thereof as contrast medium for ultrasonic diagnostics
US4501726 *11 Nov 198226 Feb 1985Schroeder UlfIntravascularly administrable, magnetically responsive nanosphere or nanoparticle, a process for the production thereof, and the use thereof
US4572203 *27 Ene 198325 Feb 1986Feinstein Steven BContact agents for ultrasonic imaging
US4657756 *8 Sep 198314 Abr 1987Schering AktiengesellschaftMicrobubble precursors and apparatus for their production and use
US4663161 *22 Abr 19855 May 1987Mannino Raphael JLiposome methods and compositions
US4675173 *8 May 198523 Jun 1987Molecular Biosystems, Inc.Method of magnetic resonance imaging of the liver and spleen
US4681119 *22 Abr 198621 Jul 1987Schering AktiengesellschaftMethod of production and use of microbubble precursors
US4684479 *14 Ago 19854 Ago 1987Arrigo Joseph S DSurfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures
US4687748 *23 Mar 198318 Ago 1987Gambro Lundia AbMagnetic carbohydrate particles as carriers for affinity separation purposes
US4718433 *5 Dic 198512 Ene 1988Feinstein Steven BContrast agents for ultrasonic imaging
US4731239 *7 Oct 198615 Mar 1988Gordon Robert TMethod for enhancing NMR imaging; and diagnostic use
US4767611 *3 Jul 198430 Ago 1988Gordon Robert TMethod for affecting intracellular and extracellular electric and magnetic dipoles
US4827945 *26 Jun 19879 May 1989Advanced Magnetics, IncorporatedBiologically degradable superparamagnetic materials for use in clinical applications
US4832941 *14 Ago 198623 May 1989Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.VContrast medium for ultrasonic examinations and process for its preparation
US4844882 *29 Dic 19874 Jul 1989Molecular Biosystems, Inc.Concentrated stabilized microbubble-type ultrasonic imaging agent
US4858208 *11 Jul 198815 Ago 1989Motorola, Inc.Apparatus and method for testing semiconductor devices
US4900540 *20 Jun 198313 Feb 1990Trustees Of The University Of MassachusettsLipisomes containing gas for ultrasound detection
US4904479 *15 Ene 198727 Feb 1990Danbiosyst Uk LimitedDrug delivery system
US4918065 *17 Oct 198817 Abr 1990Schering AktiengesellschaftCorticoid-containing preparation for topical application
US4985233 *1 Nov 198515 Ene 1991Nycomed /AsA diagnostic agent containing a non-radioactive paramagnetic metal species in a macromolecular carrier
US4986980 *1 Nov 198522 Ene 1991Nycomed AsWater-soluble, carrier-bound paramagnetic metal containing diagnostic agents
US5008109 *11 Oct 198816 Abr 1991Vestar, Inc.Vesicle stabilization
US5088499 *20 Ago 199018 Feb 1992Unger Evan CLiposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5107842 *22 Feb 199128 Abr 1992Molecular Biosystems, Inc.Method of ultrasound imaging of the gastrointestinal tract
US5141738 *18 Mar 199125 Ago 1992Schering AktiengesellschaftUltrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof
US5196348 *3 Jul 199123 Mar 1993Air Products And Chemicals, Inc.Perfluoro-crown ethers in fluorine magnetic resonance spectroscopy of biopsied tissue
US5205290 *5 Abr 199127 Abr 1993Unger Evan CLow density microspheres and their use as contrast agents for computed tomography
US5228446 *18 Jun 199120 Jul 1993Unger Evan CGas filled liposomes and their use as ultrasonic contrast agents
US5281408 *19 Ene 199325 Ene 1994Unger Evan CLow density microspheres and their use as contrast agents for computed tomography
US5310540 *13 Sep 199110 May 1994Sintetica SaMethod for the preparation of stable suspensions of hollow gas-filled microspheres suitable for ultrasonic echography
US5334381 *30 Jun 19932 Ago 1994Unger Evan CLiposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5380519 *29 Sep 199310 Ene 1995Bracco International B.V.Stable microbubbles suspensions injectable into living organisms
US5393524 *4 Jun 199328 Feb 1995Sonus Pharmaceuticals Inc.Methods for selecting and using gases as ultrasound contrast media
US5409688 *5 Jun 199225 Abr 1995Sonus Pharmaceuticals, Inc.Gaseous ultrasound contrast media
US5413774 *16 Dic 19929 May 1995Bracco International B.V.Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
US5425366 *7 Jun 199320 Jun 1995Schering AktiengesellschaftUltrasonic contrast agents for color Doppler imaging
US5445813 *12 Oct 199329 Ago 1995Bracco International B.V.Stable microbubble suspensions as enhancement agents for ultrasound echography
US5501863 *17 Ene 199526 Mar 1996Schering AktiengesellschaftContrast media synthesized from polyaldehydes
US5508021 *19 Oct 199416 Abr 1996Vivorx Pharmaceuticals, Inc.Non-fluorinated polymeric shells for medical imaging
US5512268 *6 Jun 199530 Abr 1996Vivorx Pharmaceuticals, Inc.Polymeric shells for medical imaging prepared from synthetic polymers, and methods for the use thereof
US5527521 *1 Jun 199518 Jun 1996Imarx Pharmaceutical Corp.Low density microspheres and suspensions and their use as contrast agents for computed tomography and in other applications
US5529766 *28 Mar 199225 Jun 1996Nycomed Imaging AsContrast agents
US5531980 *30 Sep 19942 Jul 1996Bracco International BvStable microbubbles suspensions injectable into living organisms
US5536489 *12 May 199516 Jul 1996Molecular Biosystems, Inc.Emulsions as contrast agents and method of use
US5536490 *28 Mar 199216 Jul 1996Nycomed Imaging AsContrast agents
US5542935 *30 Nov 19936 Ago 1996Imarx Pharmaceutical Corp.Therapeutic delivery systems related applications
US5547656 *24 May 199520 Ago 1996Imarx Pharmaceutical Corp.Low density microspheres and their use as contrast agents for computed tomography, and in other applications
US5597549 *31 Mar 199528 Ene 1997Bracco International B.V.Stable microbubble suspensions as enhancement agents for ultrasound echography
US5599523 *22 Nov 19944 Feb 1997Byk Gulden Lomberg Chemische Fabrik GmbhEcho contrast agent
US5605673 *1 Ago 199425 Feb 1997Alliance Pharmaceutical Corp.Stabilized microbubble compositions for ultrasound
US5607661 *3 Jul 19924 Mar 1997Nycomed Imaging AsAggregates of x-ray microparticles for ultrasound imaging
US5614169 *2 Jun 199525 Mar 1997Nycomed Imaging AsContrast agents, consisting of galactose particles and an amphilic carboxylic acid
US5618514 *22 Dic 19948 Abr 1997Nycomed Imaging AsDiagnostic and contrast agent
US5626833 *7 Jun 19956 May 1997Alliance Pharmaceutical Corp.Ultrasound imaging method using microbubbles
US5637289 *8 Ene 199310 Jun 1997Nycomed Imaging AsContrast agents, consisting of galactose particles
US5637564 *6 Jun 199510 Jun 1997Alliance Pharmaceutical Corp.Amphiphilic compounds derived from amino acids or peptides, their methods of synthesis and their application as drug delivery systems
US5639433 *19 Mar 199617 Jun 1997Cytec Technology Corp.Extraction of rare earth elements using alkyl phosphinic acid or salt/alkyl or aryl phosphonic acid or ester blends as extractant
US5639442 *21 Feb 199517 Jun 1997Imarx Pharmaceutical Corp.Contrast media for ultrasonic imaging
US5639443 *16 Mar 199517 Jun 1997Alliance Pharmaceutical Corp.Stabilized microbubble compositions
US5643553 *26 Sep 19951 Jul 1997Bracco International B.V.Stable microbubbles suspensions injectable into living organisms
US5648062 *5 Jun 199515 Jul 1997Nycomed Imaging AsContrast agents consisting of galactose particles
US5653959 *8 Jun 19945 Ago 1997Sintetica SaCompositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
US5658551 *1 Jun 199519 Ago 1997Bracco International B.V.Stable microbubbles suspensions injectable into living organisms
US5705187 *5 Abr 19956 Ene 1998Imarx Pharmaceutical Corp.Compositions of lipids and stabilizing materials
US5711933 *10 Ago 199427 Ene 1998Bracco International B.V.Method of making polymeric gas or air filled microballoons for ultrasonic echography
US5714528 *2 Jun 19953 Feb 1998Imarx Pharmaceutical Corp.Contrast media for ultrasonic imaging
US5714529 *5 Jun 19953 Feb 1998Imarx Pharmaceutical Corp.Contrast media for ultrasonic imaging
US5716597 *4 Jun 199310 Feb 1998Molecular Biosystems, Inc.Emulsions as contrast agents and method of use
US5718884 *3 Sep 199317 Feb 1998Nycomed Imaging AsMicrobubble-based contrast agents with crosslinked and reduced proteinaceous shells
US5720938 *7 Jun 199524 Feb 1998Alliance Pharmaceutical Corp.Systems for the formation of microbubbles
US5720939 *6 Jun 199524 Feb 1998Nycomed Imaging AsMethod of contrast enhanced magnetic resonance imaging using magnetically responsive-particles
US5730954 *13 Oct 199424 Mar 1998Schering AktiengesellschaftPreparation comprising cavitate- or clathrate-forming host/guest complexes as contrast agent
US5730955 *7 Jun 199524 Mar 1998Molecular Biosystems, Inc.Process for making gas-filled microspheres containing a liquid hydrophobic barrier
US5733572 *29 Nov 199431 Mar 1998Imarx Pharmaceutical Corp.Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5772984 *5 Jun 199530 Jun 1998Nycomed Imaging AsMethod of ultrasound imaging using microbubble-forming, solid X-ray contrast agents
US5863520 *4 Mar 199726 Ene 1999Bracco International B.V.Method of echographic imaging using polymeric gas or air filled microballoons
Clasificación de EE.UU.424/9.51, 424/9.52
Clasificación internacionalA61K49/22, A61K49/00, A61K49/18
Clasificación cooperativaA61K49/1821, A61K49/223, A61K49/1818, A61K49/225
Clasificación europeaA61K49/18R2, A61K49/18R, A61K49/22P4, A61K49/22P8
Eventos legales
2 Ago 2006ASAssignment
Effective date: 20060329
Effective date: 20060329